introduction to health economics and outcomes research ...strategic market access associate...
TRANSCRIPT
![Page 1: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/1.jpg)
www.pharmerit.com
4350 East West Highway, Suite 1110 | Bethesda, MD 20814
Introduction to Health Economics and Outcomes Research (HEOR) for Writing Professionals
Beth Lesher, Phar mD, BCPS
Cather ine O’Connor Mir v is , BA
![Page 2: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/2.jpg)
2
Agenda
Introductions
What is HEOR?
How can I break into HEOR writing/editing?
Who uses HEOR evidence?
How is HEOR evidence used?
![Page 3: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/3.jpg)
3
Presenters
Beth Lesher, PharmD, BCPS
Catherine Mirvis, BA
Sr. Communications Analyst,
Strategic Market Access
Associate Director,
Strategic Market AccessUndergrad
BS Pharm
PharmD
Critical Care Residency
Clinical Pharmacist/Academia
Medical Writing
FellowshipFreelance
NCI Internship English MajorSmithsonian
VolunteerEditorial Assistant
![Page 4: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/4.jpg)
PART 1:WHAT IS HEOR?
![Page 5: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/5.jpg)
5
Health Economics & Outcomes Research
Health Economics
Analyzes the economic aspects of health and healthcare, with a focus on the costs (inputs) and
consequences (outcomes) of healthcare interventions.
Outcomes Research
Evaluates the effect of healthcare interventions on patient-related clinical, humanistic, and
economic outcomes.
Berger et al. Health Care Cost, Quality, and Outcomes. ISPOR Book of Terms 2003
Clinical research
Clinical epidemiology
Health service research
Policy research
Health economic evaluation
Clinical outcomes assessment
![Page 6: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/6.jpg)
6
Economic
Impact of intervention on costs; direct and indirect costs derived
from clinical outcomes
Includes: Resource use, work productivity, loss of work, burden
of illness, cost-effectiveness, transportation
Evaluated using economic or pharmacoeconomic analyses
(e.g., cost-benefit, cost-effectiveness, cost-minimization,
cost-utility, budget impact models)
Examples: ICER, QALYs, PPPM, PPPY absenteeism, LOS, office
visits
Clinical
Measurable changes in health status due to an intervention
Includes: effectiveness, morbidity, mortality, function
Evaluated through clinical trials, post-marketing reports
Examples: Cure, clinical goal (HbA1c, BP), secondary
prevention, remission, adverse event rates, compliance
Humanistic
Impact of an intervention on patient-reported endpoints; also derived from clinical outcomes
Includes: Health-related quality of life (HRQOL), preference,
caregiver burden
Evaluated using general or disease-based patient/caregiver
questionnaires or surveys
Examples: SF-36, EQ-5D, patient satisfaction, patient preference, validated and unvalidated tools/surveys
What Outcomes Are Generated?E
CH
O M
OD
EL
Berger et al. Health Care Cost, Quality, and Outcomes. ISPOR Book of Terms 2003; Kozma et al. Clin Ther 1993;15:1121-32; Outcomes Research; available at
http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=19128. Accessed July 17, 2018
![Page 7: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/7.jpg)
7
Where Does HEOR Evidence Come From?
Productivity
Real-world Evidence
Prospective RCTs
Clinical Outcomes
Assessment
Surveys
Patient-reported
Outcomes
Post-marketing Studies
Observational Studies
Health Status
Registries
Meta-analyses
Clinical Studies
Claims Database Analyses
Systematic Reviews
Prospective Observational
StudiesChart Reviews
Open-label Studies
Symptoms
Indirect Treatment
Comparison
![Page 8: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/8.jpg)
8
Who Performs Outcomes Research?
Health plans/ Medical groups
Pharmacists
Government agencies
Physicians
Pharmaceutical companies
Other healthcare professionals
Nurses
Economists
Academic institutions
HTA bodies
![Page 9: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/9.jpg)
9
HEOR Evidence and Product Life Cycle
Product Approval and Launch
Preclinical • Exploratory research
• Market assessment
• Unmet needs/gap analysis
• KOL research
• Very early modelling
Phase 1 and 2• Market assessment
• Unmet needs/gap analysis
• Early modelling, early pricing models
• Burden of illness studies
• Piggyback studies
• PRO development, testing, validation
Phase 3 and 3b
• Payor assessment
• Model development/validation
• Piggyback studies
• Registries
• Comparative effectiveness research
• Value message development
• Pricing and reimbursement
• AMCP dossier
• Global value dossier
Post-launch
• Phase 4 studies
• Model refinement
• Piggyback studies
• Registries
• Comparative effectiveness research
• Prospective observational studies
• Retrospective studies
• Database analyses
• Chart reviews
• Safety surveillance
• AMCP dossier
• Global value dossier
• HTA
Loss of Exclusivity
• Safety surveillance
• Real-world studies
• Comparative effectiveness research
• Global value dossier
• HTA
![Page 10: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/10.jpg)
10
Why Do We Need HEOR Evidence?
Identify unmet needs
Supplement RCT with RWE
Address evidence gaps
Promote patient-centered research
Help develop/ evaluate cost containment strategies
Adapt data to different populations
Respond to changes in market environments
Comply with HTA submission
![Page 11: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/11.jpg)
11
Summary: Who, What, Where, When, HowW
ho • Regulators
• Patients
• HCDM
• HCP
• Politicians/Advocacy
What • Outcomes
– Economic
– Clinical
– Humanistic Where • Clinical studies
• Real-world evidence
• Patient-reported outcomes
• ModellingW
hen • Pre-clinical
• Phase 1/2
• Phase 3/Pre-launch
• Post-launch
• Loss of exclusivity
Ho
w • Product approval
• Education/awareness
• Reimbursement
• Formulary placement
• Guidelines
![Page 12: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/12.jpg)
PART 2:WRITING AND EDITING IN HEOR
![Page 13: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/13.jpg)
13
Roles for Writing Professionals in HEOR
• Dossiers
• Publications
• Value messaging
• Objection handlers
• Study reports
• Modelling reports
Writing
• Dossiers
• Publications
• Slide decks
• Reports
Editing
• Dossiers
• Publications
• Reports
Project Management
![Page 14: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/14.jpg)
14
Tips for How to Enter the HEOR Space
Leverage Your Skills
• Manuscript writing
• Editing
• Scientific background
• Slide decks
• Reports
Know Your Audience
• Journal selection
• HCDMs / Payers
• Global
• National
Know Your Resources
• ISPOR website
• AMCP format
• HealthEconomics.com
Expand Your Knowledge
• ISPOR short courses
• AMCP meetings
• HEOR meetings
![Page 15: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/15.jpg)
15
Tips for Nontechnical Backgrounds
Learn or brush up on statistics
Promote your Microsoft Word knowledge
Know your audience (HCDMs, HTAs, patients)
Don’t take your liberal arts skills for granted! • Audience analysis
• Big picture
• Writing mechanics
• Organizing ideas
Insight into non-expert audiences
AMWA workshops
Focus on your “highest and best use”
![Page 16: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/16.jpg)
16
Where Can I Get More Information?
ISPORispor.org
ISOQOLisoqol.org
AMCPamcp.org
HealthEconomics.com
PCORIpcori.org
AHRQahrq.gov
CHEERSGuidelines
NICHSRnlm.nih.gov/nichsr/hta101
![Page 17: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/17.jpg)
PART 3:HEOR EXAMPLES
![Page 18: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/18.jpg)
18
Pharmacy and Therapeutics (P&T) Committee
What is a Formulary?
What is a P&T committee?
Who is on the P&T committee?
• Pharmacists
• Doctors
• Nurses
• Lawyer
• Quality assurance
• Lay member
![Page 19: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/19.jpg)
19
Pharmacy and Therapeutics (P&T) Committee
What are their functions
• Manage education programs on drug
utilization
• Establish policies to ensure safe and
effective drug use
• Develop policies promoting cost-
effective drug use
• Provide guidance on drug distribution
and control policies
This Photo by Unknown Author is licensed under CC BY-NC-ND
![Page 20: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/20.jpg)
20
Factors Considered by P&T Committees
Clinical efficacy and effectiveness
Safety: RCT, real-world data
Therapeutic need: first in class, 5 similar agents
Clinical guidelines
Standards of practice
Treatment options
Economics: costs, PMPM costs, QALY, ICER
![Page 21: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/21.jpg)
21
Case Studies
Dose Cost, $ Efficacy Side Effects
Drug A 1 tablet daily 1.25 per tablet 77%-80% Nausea, vomiting
Drug B 1 tablet daily 1.50 per tablet 78%-80% Nausea, headache
Dose Cost, $ Efficacy Side Effects
Drug A 2 tablets daily 0.60 per tablet 77%-80% Nausea, vomiting
Drug B 1 tablet daily 1.50 per tablet 78%-80% Nausea, headache
Dose Cost, $ Efficacy Side Effects Adherence (DBA)
Drug A 1 tablet daily 1.25 per tablet 77%-80% Nausea, vomiting 65%
Drug B 1 tablet daily 1.50 per tablet 78%-80% Nausea, headache 80%
![Page 22: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/22.jpg)
22
Case Studies
Dose Cost, $ Efficacy Side Effects
Drug A 1 tablet daily 1.25 per tablet 77%-80% Nausea, vomiting, irreversible hepatotoxicity (5%)
Drug B 1 tablet daily 1.50 per tablet 78%-80% Nausea, headache
Dose Cost, $ Efficacy Side Effects Nursing Administration
Drug A 2 injections daily 30.00 per dose 77%-80% Nausea, vomiting 5 minutes
Drug B 2 injections daily 15.00 per dose
(drug cost)
78%-80% Nausea, headache IV push over 30 min,
observe for 30 min
Dose Cost, $ Efficacy Side Effects Hospital Length of Stay
Drug A 2 tablets daily 250.00 per tablet 77%-80% Nausea, vomiting 5 days
Drug B 2 injections daily 25.00 per dose
(drug cost)
78%-80% Nausea, headache 7 days / 5 days + 2 days
home IV therapy
![Page 23: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/23.jpg)
23
Case Studies
Drug A Drug B
Cost, $ 500,000 per dose 1.50 per dose
Efficacy Effective Effective
PMPM cost, $ 0.0001 0.02
Drug A Drug B
Dose 1 injections daily 2 injections daily
Cost, $ 30.00 per dose 10.00 per dose (drug cost)
Efficacy 80% 60%
Side effects Nausea, vomiting, severe rash Nausea, headache
Nursing administration IV push over 10 minutes IV push over 10 minutes
Laboratory testing Q day (renal) Q 3 days (renal panel, CBC)
ICU time 1 day 1.5 days
Ventilator time 0.5 day 1 day
![Page 24: Introduction to Health Economics and Outcomes Research ...Strategic Market Access Associate Director, Undergrad Strategic Market Access BS Pharm PharmD Critical Care Residency Clinical](https://reader034.vdocuments.us/reader034/viewer/2022042515/5f52432c598854762c6701ac/html5/thumbnails/24.jpg)
24
Questions?